Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (21-30 of 210) with videos related to

Pageof 21
Sort By:
Cancers|March 29, 2023
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel TargetsNadia Ashai, Sandra M Swain
JAMA Oncology|June 30, 2016
Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?Ana Barac, Sandra M Swain
Cancer Investigation|June 13, 2014
Pertuzumab for the treatment of breast cancerFilipa Lynce, Sandra M Swain
JAMA|October 17, 2013
Drug discount programSandra M Swain, Jeffery C Ward
The Oncologist|March 18, 2016
Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?Michael S Ewer, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Contralateral breast cancer: where does it all begin?Suparna Bonthala Wedam, Sandra M Swain
Seminars in Oncology|December 20, 2005
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)James J Lee, Sandra M Swain
Seminars in Oncology|July 26, 2002
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapyAntoinette R Tan, Sandra M Swain
Clinical Breast Cancer|December 31, 2005
Concepts and clinical trials of dose-dense chemotherapy for breast cancer Jennifer A Orzano, Sandra M Swain
Seminars in Oncology|November 13, 2003
Ongoing adjuvant trials with trastuzumab in breast cancerAntoinette R Tan, Sandra M Swain
Pageof 21

Showing results (21-30 of 210) with videos related to

Sort By:
Pageof 21
Cancers|March 29, 2023
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel TargetsNadia Ashai, Sandra M Swain
JAMA Oncology|June 30, 2016
Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?Ana Barac, Sandra M Swain
Cancer Investigation|June 13, 2014
Pertuzumab for the treatment of breast cancerFilipa Lynce, Sandra M Swain
JAMA|October 17, 2013
Drug discount programSandra M Swain, Jeffery C Ward
The Oncologist|March 18, 2016
Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?Michael S Ewer, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Contralateral breast cancer: where does it all begin?Suparna Bonthala Wedam, Sandra M Swain
Seminars in Oncology|December 20, 2005
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)James J Lee, Sandra M Swain
Seminars in Oncology|July 26, 2002
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapyAntoinette R Tan, Sandra M Swain
Clinical Breast Cancer|December 31, 2005
Concepts and clinical trials of dose-dense chemotherapy for breast cancer Jennifer A Orzano, Sandra M Swain
Seminars in Oncology|November 13, 2003
Ongoing adjuvant trials with trastuzumab in breast cancerAntoinette R Tan, Sandra M Swain
Pageof 21